August 29, 2025 — Rocket Doctor AI Inc. (CSE: AIDR; OTC: TREIF; FFA: 939) has announced its financial results for the second quarter ended June 30, 2025, reporting Q2 revenue of $0.5 million, driven by the Rocket Doctor acquisition, and a net comprehensive loss of $2.7 million, or $0.04 per share. The company closed the acquisition of Rocket Doctor Inc., adding a platform that supports over 300 clinicians and 600,000+ patient visits to date and launched a virtual-care partnership with Central California Alliance for Health (Medi-Cal), serving approximately 450,000 members. Rocket Doctor AI also saw successful live deployment of the Medical Education Suite (MES) to 240 University of Minnesota medical students. All financial information is presented in Canadian dollars unless otherwise indicated.
Dr. Essam Hamza, CEO of Rocket Doctor AI Inc., expressed excitement about the company’s first significant revenue-producing quarter, highlighting the completion of the Rocket Doctor Inc. acquisition, advancement of their GLM technology, and new contracts contributing to U.S. expansion.
Q2 2025 gross margin was 89%, compared to 0% in Q1 2025 and Q2 2024, attributed to revenue from Rocket Doctor Inc.’s digital health platform and marketplace. Adjusted EBITDA was a loss of $1.7 million in Q2 2025, compared to a loss of $1.2 million in Q1 2025 and a loss of $2.3 million in Q2 2024.
Corporate highlights include the acquisition of Rocket Doctor Inc. on April 10, being named Clinical Innovator of the Year at the Innovators Challenge during NEXUS 2025, partnering with Melanoma Canada on May 20, the successful deployment of Treatment.com AI’s new Medical Education Suite (MES) at the University of Minnesota Medical School on June 11, and the launch of Rocket Doctor Inc.’s virtual care partnership with Central California Alliance for Health on June 24.
The Company operates at the intersection of artificial intelligence and digital health through its subsidiaries Treatment.com Inc., Rocket Doctor Inc., and Rocket Doctor, Inc., utilizing its Global Library of Medicine (“GLM”) to provide clinical decision support, educational tools, and digital platforms.
Dr. Essam Hamza, CEO, essam.hamza@rocketdoctor.ai
For media inquiries, contact: media@rocketdoctor.ai
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Source: Rocket Doctor AI Inc.
